

# Antonis Fanouriakis

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8471883/publications.pdf>

Version: 2024-02-01

111  
papers

3,522  
citations

257450  
24  
h-index

149698  
56  
g-index

113  
all docs

113  
docs citations

113  
times ranked

3228  
citing authors

#	ARTICLE	IF	CITATIONS
1	2019 update of the EULAR recommendations for the management of systemic lupus erythematosus. Annals of the Rheumatic Diseases, 2019, 78, 736-745.	0.9	1,265
2	2019 Update of the Joint European League Against Rheumatism and European Renal Association–European Dialysis and Transplant Association (EULAR/ERA–EDTA) recommendations for the management of lupus nephritis. Annals of the Rheumatic Diseases, 2020, 79, 713-723.	0.9	463
3	Update in the diagnosis and management of systemic lupus erythematosus. Annals of the Rheumatic Diseases, 2021, 80, 14-25.	0.9	312
4	Combined genetic and transcriptome analysis of patients with SLE: distinct, targetable signatures for susceptibility and severity. Annals of the Rheumatic Diseases, 2019, 78, 1079-1089.	0.9	109
5	Diagnostic criteria for systemic lupus erythematosus: has the time come?. Nature Reviews Rheumatology, 2013, 9, 687-694.	8.0	103
6	Pathogenic and Therapeutic Relevance of JAK/STAT Signaling in Systemic Lupus Erythematosus: Integration of Distinct Inflammatory Pathways and the Prospect of Their Inhibition with an Oral Agent. Cells, 2019, 8, 898.	4.1	95
7	In an early SLE cohort the ACR-1997, SLICC-2012 and EULAR/ACR-2019 criteria classify non-overlapping groups of patients: use of all three criteria ensures optimal capture for clinical studies while their modification earlier classification and treatment. Annals of the Rheumatic Diseases, 2020, 79, 232-241.	0.9	71
8	Epidemiology and burden of systemic lupus erythematosus in a Southern European population: data from the community-based lupus registry of Crete, Greece. Annals of the Rheumatic Diseases, 2017, 76, 1992-2000.	0.9	68
9	Low disease activity “irrespective of serologic status at baseline” associated with reduction of corticosteroid dose and number of flares in patients with systemic lupus erythematosus treated with belimumab: A real-life observational study. Seminars in Arthritis and Rheumatism, 2018, 48, 467-474.	3.4	59
10	Lupus or not? SLE Risk Probability Index (SLERPI): a simple, clinician-friendly machine learning-based model to assist the diagnosis of systemic lupus erythematosus. Annals of the Rheumatic Diseases, 2021, 80, 758-766.	0.9	50
11	Pathogenesis and treatment of CNS lupus. Current Opinion in Rheumatology, 2013, 25, 577-583.	4.3	49
12	Liver safety of non-tumour necrosis factor inhibitors in rheumatic patients with past hepatitis B virus infection: an observational, controlled, long-term study. Clinical and Experimental Rheumatology, 2018, 36, 102-109.	0.8	49
13	EULAR recommendations for neuropsychiatric systemic lupus erythematosus vs usual care: results from two European centres. Rheumatology, 2015, 54, 1270-1278.	1.9	48
14	Cyclophosphamide in combination with glucocorticoids for severe neuropsychiatric systemic lupus erythematosus: a retrospective, observational two-centre study. Lupus, 2016, 25, 627-636.	1.6	45
15	Neuropsychiatric lupus or not? Cerebral hypoperfusion by perfusion-weighted MRI in normal-appearing white matter in primary neuropsychiatric lupus erythematosus. Annals of the Rheumatic Diseases, 2018, 77, 441-448.	0.9	43
16	Changing paradigms in the treatment of systemic lupus erythematosus. Lupus Science and Medicine, 2019, 6, e000310.	2.7	40
17	Management of lupus nephritis: a systematic literature review informing the 2019 update of the joint EULAR and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations. RMD Open, 2020, 6, e001263.	3.8	39
18	Validity of the Italian algorithm for the attribution of neuropsychiatric events in systemic lupus erythematosus: a retrospective multicentre international diagnostic cohort study. BMJ Open, 2017, 7, e015546.	1.9	35

#	ARTICLE	IF	CITATIONS
19	Cerebrovascular Events in Systemic Lupus Erythematosus: Diagnosis and Management. Mediterranean Journal of Rheumatology, 2019, 30, 7-15.	0.8	33
20	Evolving phenotype of systemic lupus erythematosus in Caucasians: low incidence of lupus nephritis, high burden of neuropsychiatric disease and increased rates of late-onset lupus in the "Attikon"™ cohort. Lupus, 2020, 29, 514-522.	1.6	31
21	Hepatitis B reactivation following treatment with abatacept in a patient with past hepatitis B virus infection. Rheumatology, 2014, 53, 195-196.	1.9	29
22	Coexistence of systemic lupus erythematosus and multiple sclerosis: Prevalence, clinical characteristics, and natural history. Seminars in Arthritis and Rheumatism, 2014, 43, 751-758.	3.4	26
23	Canakinumab for recurrent rheumatic disease associated-pericarditis: a case series with long-term follow-up. Rheumatology, 2018, 57, 1494-1495.	1.9	26
24	Targeted Biologic Therapy for Systemic Lupus Erythematosus: Emerging Pathways and Drug Pipeline. BioDrugs, 2020, 34, 133-147.	4.6	25
25	Rituximab for eosinophilic granulomatosis with polyangiitis with severe vasculitic neuropathy: Case report and review of current clinical evidence. Seminars in Arthritis and Rheumatism, 2015, 45, 60-66.	3.4	24
26	Is it primary neuropsychiatric systemic lupus erythematosus? Performance of existing attribution models using physician judgment as the gold standard. Clinical and Experimental Rheumatology, 2016, 34, 910-917.	0.8	24
27	Cognitive deficits early in the course of rheumatoid arthritis. Journal of Clinical and Experimental Neuropsychology, 2016, 38, 820-829.	1.3	23
28	Update on the pathogenesis of central nervous system lupus. Current Opinion in Rheumatology, 2019, 31, 669-677.	4.3	22
29	Rheumatology training experience across Europe: analysis of core competences. Arthritis Research and Therapy, 2016, 18, 213.	3.5	19
30	Transition to severe phenotype in systemic lupus erythematosus initially presenting with non-severe disease: implications for the management of early disease. Lupus Science and Medicine, 2020, 7, e000394.	2.7	18
31	Clinical outcomes of breakthrough COVID-19 after booster vaccination in patients with systemic rheumatic diseases. RMD Open, 2022, 8, e002279.	3.8	18
32	Regional cerebral perfusion correlates with anxiety in neuropsychiatric SLE: evidence for a mechanism distinct from depression. Lupus, 2019, 28, 1678-1689.	1.6	17
33	Lymphopenia as a risk factor for neurologic involvement and organ damage accrual in patients with systemic lupus erythematosus: A multi-center observational study. Seminars in Arthritis and Rheumatism, 2020, 50, 1387-1393.	3.4	16
34	SAT0173...A SYSTEMATIC LITERATURE REVIEW INFORMING THE 2019 UPDATE OF THE JOINT EUROPEAN LEAGUE AGAINST RHEUMATISM AND EUROPEAN RENAL ASSOCIATION "EUROPEAN DIALYSIS AND TRANSPLANT ASSOCIATION (EULAR/ERA-EDTA) RECOMMENDATIONS FOR THE MANAGEMENT OF LUPUS NEPHRITIS. Annals of the Rheumatic Diseases, 2020, 79, 1028.2-1028.	0.9	16
35	Educational needs and preferences of young European clinicians and physician researchers working in the field of rheumatology. RMD Open, 2016, 2, e000240.	3.8	14
36	Population-based studies in systemic lupus erythematosus: immune thrombocytopenic purpura or "blood-dominant"™ lupus?. Annals of the Rheumatic Diseases, 2020, 79, 683-684.	0.9	14

#	ARTICLE	IF	CITATIONS
37	Inflammatory Arthritis Induced by Pembrolizumab in a Patient With Head and Neck Squamous Cell Carcinoma. <i>Frontiers in Oncology</i> , 2018, 8, 409.	2.8	11
38	Hydroxychloroquine dosing in systemic lupus erythematosus: response to “Comment on the 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus by Fanouriakis et al” by Costedoat-Chalumeau et al. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, e91-e91.	0.9	11
39	Is systemic lupus erythematosus different in urban versus rural living environment? Data from the Cretan Lupus Epidemiology and Surveillance Registry. <i>Lupus</i> , 2019, 28, 104-113.	1.6	10
40	Treatment of neuropsychiatric systemic lupus erythematosus: clinical challenges and future perspectives. <i>Expert Review of Clinical Immunology</i> , 2021, 17, 317-329.	3.0	10
41	Molecular Taxonomy of Systemic Lupus Erythematosus Through Data-Driven Patient Stratification: Molecular Endotypes and Cluster-Tailored Drugs. <i>Frontiers in Immunology</i> , 2022, 13, .	4.8	10
42	2008–2018: a decade of recommendations for systemic lupus erythematosus. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, 1547-1548.	0.9	9
43	Geoeidemiology and clinical characteristics of neonatal lupus erythematosus: a systematic literature review of individual patients’ data. <i>Turkish Journal of Medical Sciences</i> , 2020, 44, 281-290.	0.9	9
44	Anxiety and depression severity in neuropsychiatric SLE are associated with perfusion and functional connectivity changes of the frontolimbic neural circuit: a resting-state functional MRI study. <i>Lupus Science and Medicine</i> , 2021, 8, e000473.	2.7	9
45	Quality indicators for systemic lupus erythematosus based on the 2019 EULAR recommendations: development and initial validation in a cohort of 220 patients. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 1175-1182.	0.9	9
46	Demyelinating Syndromes in Systemic Lupus Erythematosus: Data From the “Attikon” Lupus Cohort. <i>Frontiers in Neurology</i> , 2022, 13, .	2.4	8
47	Adaptation to an autoimmune disorder: Does mental flexibility impact illness-related self-regulation?. <i>Psychology and Health</i> , 2016, 31, 276-291.	2.2	6
48	FRIO193–2019 UPDATE OF THE EULAR RECOMMENDATIONS FOR THE MANAGEMENT OF SYSTEMIC LUPUS ERYTHEMATOSUS. , 2019, , .		6
49	Demyelination with autoimmune features: a distinct clinical entity? Results from a longitudinal cohort. <i>Rheumatology</i> , 2021, 60, 4166-4174.	1.9	6
50	First Diagnosis of Systemic Lupus Erythematosus in Hospitalized Patients: Clinical Phenotypes and Pitfalls for the Non-Specialist. <i>American Journal of Medicine</i> , 2022, 135, 244-253.e3.	1.5	6
51	Editorial: Lupus and the Brain: Advances in Neuropsychiatric Systemic Lupus Erythematosus. <i>Frontiers in Medicine</i> , 2019, 6, 52.	2.6	5
52	Screening for cognitive impairment in systemic lupus erythematosus: Application of the Montreal Cognitive Assessment (MoCA) in a Greek patient sample. <i>Lupus</i> , 2021, 30, 2237-2247.	1.6	5
53	Treatment of lupus: more options after a long wait. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 753-756.	0.9	5
54	Tailored treatment strategies and future directions in systemic lupus erythematosus. <i>Rheumatology International</i> , 2022, 42, 1307-1319.	3.0	5

#	ARTICLE	IF	CITATIONS
55	Treat-to-target in lupus: what does the future hold?. International Journal of Clinical Rheumatology, 2015, 10, 461-477.	0.3	4
56	Converging evidence of impaired brain function in systemic lupus erythematosus: changes in perfusion dynamics and intrinsic functional connectivity. Neuroradiology, 2022, 64, 1593-1604.	2.2	4
57	Remission or low disease activity at pregnancy onset are linked to improved foetal outcomes in women with systemic lupus erythematosus: results from a prospective observational study. Clinical and Experimental Rheumatology, 0, , .	0.8	4
58	Balancing efficacy and toxicity of novel therapies in systemic lupus erythematosus. Expert Review of Clinical Pharmacology, 2011, 4, 437-451.	3.1	3
59	Treatment of Systemic Lupus Erythematosus. , 2017, , 1368-1388.e5.		3
60	Recent progress in the treatment of lupus nephritis. Modern Rheumatology, 2012, 22, 803-813.	1.8	3
61	Performance of the systemic lupus erythematosus risk probability index in a cohort of undifferentiated connective tissue disease. Rheumatology, 2022, 61, 3606-3613.	1.9	3
62	In early arthritis patients, high HAQ at baseline and DAS28 at three months predict suboptimal outcomes at two years: a retrospective cohort study. Clinical and Experimental Rheumatology, 2018, 36, 806-813.	0.8	3
63	SP0189â€¦UPDATE ON EULAR RECOMMENDATIONS FOR THE MANAGEMENT OF SLE. , 2019, , .		2
64	Advances in Systemic Lupus Erythematosus (SLE): A case for optimism. Mediterranean Journal of Rheumatology, 2017, 28, 1-3.	0.8	2
65	Development and Implementation of a Pilot Registry for Monitoring the Efficacy and Safety of Novel Therapies in Patients with Systemic Lupus Erythematosus. Mediterranean Journal of Rheumatology, 2019, 31, 87.	0.8	2
66	Septic Arthritis Complicating a Gout Flare: Report of Two Cases and Review of the Literature. Mediterranean Journal of Rheumatology, 2022, 33, 75.	0.8	2
67	Control of flares and relief of urate burden with canakinumab and targeted urate-lowering therapy in tophaceous gouty arthritis. Rheumatology, 2014, 53, 764-766.	1.9	1
68	Paraneoplastic digital ischemia in clear-cell renal-cell carcinoma: Report of a case and review of the literature. Urologia, 2019, 86, 156-160.	0.7	1
69	THU0254â€¦TRENDS OF SEVERITY, PROGRESSION AND BURDEN OF DISEASE IN THE â€œATTIKONâ€•SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) COHORT: EVIDENCE FOR THE RULE OF â€œONE THIRDâ€•IN DISEASE SEVERITY. , 2019, , .		1
70	Response to: â€™Neuropsychiatric lupus or not? Cerebral hypoperfusion by perfusion-weighted MRI in normal-appearing white matter in primary neuropsychiatric lupus erythematosus' by Papadaki<i>et al'</i>by Wallace. Annals of the Rheumatic Diseases, 2019, 78, e6-e6.	0.9	1
71	Chloroquine as alternative antimalarial in systemic lupus erythematosus. Response to â€™2019 update of the EULAR recommendations for the management of SLE: donâ€™t forget chloroquineâ€™ by Figueroa-Parra <i>et al</i>. Annals of the Rheumatic Diseases, 2020, 79, e115-e115.	0.9	1
72	Response to: â€™Treatment of systemic lupus erythematosus: donâ€™t forget hydroxychloroquineâ€™ by Michaud <i>et al</i>. Annals of the Rheumatic Diseases, 2020, 79, e134-e134.	0.9	1

#	ARTICLE	IF	CITATIONS
73	Response to: "Concerns about the operational definition of remission in 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus"™ by Rua-Figueroa and Erausquin. Annals of the Rheumatic Diseases, 2020, 79, e132-e132.	0.9	1
74	Response to: "Bone health, an often forgotten comorbidity in systemic lupus erythematosus: a comment on the new recommendations"™ by Orsolini et al. Annals of the Rheumatic Diseases, 2020, 79, e151-e151.	0.9	1
75	A5.26"Regulation of Expression and Function of Negative Immunomodulatory Receptors in B-Cells: Implications for the Pathogenesis of Systemic Lupus Erythematosus. Annals of the Rheumatic Diseases, 2013, 72, A40.1-A40.	0.9	0
76	SAT0054"Favorable Long-Term Outcome of Early Inflammatory Arthritis in Clinical Practice: High Baseline Haq and Das28 at 3 Months Predict Use of Biologics. Annals of the Rheumatic Diseases, 2016, 75, 683.1-683.	0.9	0
77	FRI0316"Assessing Attribution of Neuropsychiatric Events in Systemic Lupus Erythematosus. Performance of A New Algorithm in An International Multicenter Cohort. Annals of the Rheumatic Diseases, 2016, 75, 549.2-550.	0.9	0
78	FRI0218"Safety of Non Anti-TNF Biologic Agents in Rheumatic Patients with Past Hepatitis B Virus Infection. A Single-Center Real-Life Study. Annals of the Rheumatic Diseases, 2016, 75, 511.1-511.	0.9	0
79	OP0332"The genomic architecture of systemic lupus erythematosus (SLE) by RNA-SEQ: distinct disease susceptibility, activity and severity signatures and extensive genetic effects on whole blood gene expression. , 2017, , .		0
80	THU0254"Comparison of urban versus rural environment associated systemic lupus erythematosus (SLE): risk and clinical features. , 2017, , .		0
81	SAT0204"Abatacept survival in rheumatoid arthritis patients at 2 years is 59%; its use as a 2nd line biologic agent and lower baseline haq predict better survival in clinical practice: a prospective, observational single center study. , 2017, , .		0
82	THU0246"The impact of classifying SLE patients with the SLICC-2012 versus the ACR-1997 classification criteria on early diagnosis, severity, and damage: data from the community-based cretan lupus registry. , 2017, , .		0
83	FRI0269"if it's not multiple sclerosis, look for a connective tissue disease" atypical demyelinating disorders referred to a tertiary rheumatology centre. , 2017, , .		0
84	FRI0244"Low dose of rituximab is effective for maintenance of clinical remission or low disease activity in patients with rheumatoid arthritis. , 2017, , .		0
85	AB0442"Real-life experience with belimumab in systemic lupus erythematosus (SLE): control of disease activity and flares in a multicenter cohort. , 2017, , .		0
86	AB0471"Wide heterogeneity in treatment protocols and inappropriate use of prednisolone for anti-ro/la associated-congenital heart block: a systematic review of 492 cases. , 2017, , .		0
87	FRI0236"After discontinuation of the 1st tumor necrosis factor inhibitor (TNFi), non-tnfi biologic agents have similar responses but higher survival compared to a 2nd course of a different tnfi: long-term prospective observational study of patients with rheumatoid arthritis in a tertiary hospital of greece. , 2017, , .		0
88	P009"Transcriptomic analysis of plasmacytoid dendritic cells from rheumatoid arthritis patients reveals novel targets for therapy. , 2018, , .		0
89	AB0503"Therapeutic strategy and short-term outcome in neuropsychiatric systemic lupus erythematosus. , 2018, , .		0
90	FRI0225"THE EULAR/ACR 2018 AND SLICC 2012 HAVE INCREASED SENSITIVITY AGAINST THE ACR 1997 CLASSIFICATION CRITERIA AND CLASSIFY NON-OVERLAPPING GROUPS OF SLE PATIENTS: SIMULTANEOUS APPLICATION ASSURES THE GREATEST CAPTURE OF PATIENTS IN CLINICAL PRACTICE. , 2019, , .		0



#	ARTICLE	IF	CITATIONS
91	THU0284â€¦WHAT DO HEMATOLOGICAL ABNORMALITIES TELL US IN SLE? RESULTS FROM TWO INDEPENDENT MULTICENTER EUROPEAN SLE COHORTS. , 2019, , .		0
92	FRI0192â€¦A SYSTEMATIC LITERATURE REVIEW TO INFORM THE 2019 UPDATE OF THE EULAR RECOMMENDATIONS FOR THE TREATMENT OF SYSTEMIC LUPUS ERYTHEMATOSUS. , 2019, , .		0
93	SP0078â€¦CASE PRESENTER: LONGSTANDING NEURO LUPUS IN ADULT LIFE. , 2019, , .		0
94	P150â€¦The evolving clinical presentation of systemic lupus erythematosus in a newly established caucasian cohort: low incidence of lupus nephritis and high burden of neuropsychiatric disease. , 2020, , .		0
95	P151â€¦Demyelination with autoimmune features (DAF) â€œ results from the attikon cohort. , 2020, , .		0
96	Diffuse oesophageal involvement in anti-NXP2 myositis and response to combined immunosuppressive therapy. Rheumatology, 2021, 60, e378-e380.	1.9	0
97	Response to: Correspondence on â€œUpdate on the diagnosis and management of systemic lupus erythematosusâ€•by Zhou<i>et al</i>. Annals of the Rheumatic Diseases, 2023, 82, e192-e192.	0.9	0
98	Developing novel drugs for systemic lupus erythematosus. Lessons learned from the belimumab trials. Reviews in Health Care, 2012, 3, 209-222.	0.1	0
99	THU0072â€¦Gene signature of plasmacytoid dendritic cells reveals novel pathways contributing to tolerance in rheumatoid arthritis patients. , 2018, , .		0
100	SP0100â€¦Neuropsychiatric lupus or not?. , 2018, , .		0
101	Birth Registry of Women with Systemic Lupus Erythematosus: The Greek Experience. Mediterranean Journal of Rheumatology, 2018, 29, 228-231.	0.8	0
102	Comparative analysis of the sensitivity and specificity of the classification criteria and correlation with prognosis of disease in patients with Systemic Lupus Erythematosus. Mediterranean Journal of Rheumatology, 2018, 29, 232-235.	0.8	0
103	Response to: â€œHydroxychloroquine is neutral in risk of chronic kidney disease in patients with systemic lupus erythematosusâ€™ by Wuet al. Annals of the Rheumatic Diseases, 2020, , annrheumdis-2020-217804.	0.9	0
104	FRI0543â€¦BIRTH REGISTRY OF WOMEN WITH SYSTEMATIC LUPUS ERYTHEMATOSUSAND COURSE OF THE DISEASE DURING FIRST YEARS POST-PARTUM-THE GREEK EXPERIENCE. Annals of the Rheumatic Diseases, 2020, 79, 872.2-873.	0.9	0
105	FRI0155â€¦â†• MULTICENTER â€œAT-RISKâ€•COHORT FOR THE DISCOVERY OF ENVIRONMENTAL, CLINICAL AND MOLECULAR PREDICTORS FOR THE TRANSITION INTO SYSTEMIC LUPUS ERYTHEMATOSUS (SLE). Annals of the Rheumatic Diseases, 2020, 79, 661.1-661.	0.9	0
106	THU0245â€¦PENALIZED REGRESSION ANALYSIS IDENTIFIES CRITERIA AND NON-CRITERIA FEATURES THAT MAY INCREASE THE ACCURACY OF EXISTING SETS OF CRITERIA FOR CLASSIFYING SYSTEMIC LUPUS ERYTHEMATOSUS (SLE). Annals of the Rheumatic Diseases, 2020, 79, 349.3-350.	0.9	0
107	FRI0170â€¦THERAPEUTIC ÎTARGETS AND QUALITY INDICATORS IN SYSTEMIC LUPUS ERYTHEMATOSUS (SLE), DEFINED ACCORDING TO THE 2019 UPDATE OF THE EULAR RECOMMENDATIONS: DATA FROM THE â€œATTIKONâ€• LUPUS COHORT. Annals of the Rheumatic Diseases, 2020, 79, 669.2-670.	0.9	0
108	Periaortitis and diffuse subendocardial vasculitis in a patient with systemic lupus erythematosus â€œ Lupus flare or a coexisting disease?. Mediterranean Journal of Rheumatology, 2020, 31, 216.	0.8	0

#	ARTICLE	IF	CITATIONS
109	Evolving Concepts in Systemic Lupus Erythematosus. Israel Medical Association Journal, 2016, 18, 749-753.	0.1	0
110	The relation of partnersâ€™ illness representations to the coping behaviors of patients with inflammatory rheumatic diseases through patientsâ€™ illness representation: A dyadic regulation process. Current Psychology, 0, , 1.	2.8	0
111	Remission or low disease activity at pregnancy onset are linked to improved foetal outcomes in women with systemic lupus erythematosus: results from a prospective observational study.. Clinical and Experimental Rheumatology, 2022, , .	0.8	0